Eisai R&d Management Co., Ltd.

Nichiha Corp.

Eisai Company, Limited

Yoshino Kogyosho Co., Ltd.

Other

Shionogi & Company Limited

Chiba University

Jfe Engineering Corporation

Toshio Imai

Kenzo Muramoto

Miyuki Nishimura

Yoshimasa Sakamoto

Tetsu Kawano

Yuichi Ono

Keiko Yamaguchi

Luigi Grasso

Eiji Inoue

Jared Spidel

Tatsuo Horizoe

Akio Yamada

Aki Nakatani

Hiroaki Yamamoto

Yoshimi Takai

Yoshikazu Kuboi

James Bradford Kline

Masakazu Takeuchi

Tomomi Kawakatsu

Mayumi Asano

Koji Morimoto

Maki Deguchi

Yoko Inoue

Toshifumi Hirayama

Toshinori Nakayama

Tetsuya Yoshida

Makoto Takada

Yoshinori Hibino

Yasuko Nakagawa

Shuichi Koshio

Osamu Yoshie

Shunsuke Ito

Koji Hayashizaki

Takahiro Yamaguchi

Hiroshi Tonomura

Yoshihisa Arita

Daisuke Tokita

Ryota Taguchi

Toshifumi Takahashi

Taro Enjoji

Keiko Mizuno

Brad Kline

Motoko Kimura

Hirohisa Yamazaki

Nobuhiro Hasegawa

Hiroshi Nagamine

Hayato Nakazono

Jungo Kakuta

Ryu Gejima

Yukihisa Sawa

Naoyuki Kojima

Hideaki Ogasawara

Provided is an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4, as well as a pharmaceutical composition comprising the antibody as the active ingredient. A mouse anti-EphA4 antibody that has binding affinity towards EphA4 and can enhance the cleavage of EphA4 was obtained, and the sequence of the complementarity-determining region (CDR) of the mouse anti-EphA4 antibody was identified. Subsequently, the anti-EphA4 antibody of interest was obtained by producing a humanized antibody of the mouse anti-EphA4 antibody.

Anti-EphA4 antibody

The present invention provides an anti-Myl9 antibody or a Myl9 binding fragment thereof that binds to Myl9 and may inhibit the interaction between Myl9 and CD69 in humans, as well as a pharmaceutical composition comprising the same. A mouse anti-human/mouse Myl9 monoclonal antibody having binding affinity against Myl9 was obtained, and the sequence for the complementarity determining region (CDR) of said mouse anti-human/mouse Myl9 monoclonal antibody was identified. Accordingly, a humanized antibody comprising the CDR sequence of said mouse anti-human/mouse Myl9 monoclonal antibody in the variable region of heavy and light chains was produced.

Anti-MYL9 antibody

It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

The present invention relates to polynucleotide probes and antibodies for detecting Lrp4/Corin dopaminergic neuron progenitor cell markers, which enable the efficient separation of dopaminergic neuron progenitor cells; and methods for selecting the progenitor cells by the use thereof.

Lrp4/corin dopamine-producing neuron precursor cell marker

A buckling pattern steel pipe for being buried in ground in which flexure occurs includes: a steel pipe straight portion; and a buckling pattern portion. The buckling pattern portion is in a shape expressed by a sine wave determined based on: a buckling wavelength which is 2.05 to 4.32 times a compression local buckling half wavelength expressed by 1.72&#x221a;(r&#xb7;T); and a crest height expressed by a value 8.00 to 16.25 times a pipe thickness of the steel pipe straight pipe portion, and the buckling pattern portion absorbs bending compression deformation caused by faulting of the ground and axial compression deformation caused by the flexure so as to avoid deformation of the steel pipe straight pipe portion, where r is a pipe thickness center radius of the steel pipe straight pipe portion and T is the pipe thickness of the steel pipe straight pipe portion.

Buckling pattern steel pipe

The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

Neutralizing anti-CCL20 antibodies

The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

Methods for detecting Th1 cells

An object of the present invention is to provide a monoclonal antibody binding to human XCR1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of SEQ ID NO: 91.

Anti-human XCR1 antibodies

Nucleic acids encoding neutralizing anti-CCL20 antibodies

The present invention features compositions and methods related to humanized antibodies and FKN-binding fragments thereof that bind fractalkine.

Compositions and methods for treating inflammatory disorders

A building material and a method for coating a substrate for the building material with a coating film having a variety of functions relating to an environment such as mildew resistance, deodorization, antibacterial activity and air purification in addition to the anti-staining effect by having an excellent hydrophilicity. The method for coating the substrate for a building material comprises the steps of; coating a coating material comprising a hydrophilic polymer and a photocatalyst on the substrate, and drying the coating material to form a coating film containing the photocatalyst, wherein the hydrophilic polymer is at least one selected from the group consisting of methyl silicate, liquid glass, colloidal silica, poly(meth)acrylate, and polytetrafluoroethylene graft-polymerized with sulfonic acid, and the photocatalyst is at least one selected from the group consisting of titanium oxide coated with zeolite, titanium oxide coated silica and titanium oxide coated with apatite.

Coating film for building material

A therapeutic agent for an inflammatory disease comprising an antibody or a CX3CR1 antagonist that inhibits an interaction of fractalkine and CX3CR1 is provided.

Treating inflammatory diseases with antibodies that inhibit fractalkine-CXCR1 interaction

Growing community of inventors

Kyoto, Japan

Toshio Imai